Crystalvue Medical Co Ltd (6527) AI Stock Analysis

Crystalvue Medical Co Ltd

(TPEx:6527)

Select Model

Rating:70.9Outperform

Price Target:TWD 80.00▲(9.74% Upside)

Action:initiatedcoverage

Date:11/10/26

Strong profitability, very low leverage, and attractive valuation are the main strengths. These are offset by weak cash conversion and mildly negative technical momentum, resulting in a moderately favorable overall score.

Positive Factors

Very Low LeverageVery low leverage reduces financial risk and leaves the company with substantial flexibility to fund operations, absorb weaker periods, or pursue growth without relying heavily on creditors. This conservative financing structure should remain supportive over the next several quarters.

Negative Factors

Negative Free Cash FlowFree cash flow turning negative weakens the quality of reported earnings because less cash is available for dividends, reinvestment, or strategic flexibility. If this condition persists, the company may need to rely more heavily on existing cash resources or external financing.

Crystalvue Medical Co Ltd (6527) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 1.88B
Dividend Yield: 3.98%
Average Volume (3M): 18.03K
Price to Earnings (P/E): 12.1
Beta (1Y): 0.20
Revenue Growth: -1.23%
EPS Growth: 10.20%
Country: TW
Employees: 109
Sector: General
Sector Strength: 55
Industry: Medical - Instruments & Supplies

Crystalvue Medical Co Ltd Business Overview & Revenue Model

Company Description

Based in Taoyuan City, Taiwan, and established in 2009, Crystalvue Medical Corporation operates internationally, specializing in the design, production, and distribution of ophthalmic medical devices. Their comprehensive product range encompasses ins...

Crystalvue Medical Co Ltd Financial Statement Overview

Summary

Strong profitability and an exceptionally conservative balance sheet support the score, but declining operating cash flow and negative free cash flow materially reduce it.

Income Statement

88Very Positive

Balance Sheet

95Very Positive

Cash Flow

55Neutral

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	874.21M	949.05M	868.03M	823.96M	795.46M	721.61M
Gross Profit	322.82M	331.88M	299.14M	266.75M	261.74M	211.39M
EBITDA	184.71M	198.76M	189.36M	149.73M	169.59M	151.22M
Net Income	148.53M	146.98M	127.15M	103.40M	115.03M	77.24M
Balance Sheet
Total Assets	1.36B	1.30B	1.18B	1.08B	1.01B	938.51M
Cash, Cash Equivalents and Short-Term Investments	84.02M	132.02M	241.64M	276.36M	178.55M	200.78M
Total Debt	38.25M	11.70M	18.46M	25.03M	31.41M	37.61M
Total Liabilities	323.96M	266.79M	246.39M	221.37M	237.32M	219.61M
Stockholders Equity	1.03B	1.03B	938.53M	857.06M	775.66M	718.90M
Cash Flow
Free Cash Flow	-41.08M	-46.06M	21.01M	145.47M	42.75M	-288.70M
Operating Cash Flow	161.19M	139.13M	153.06M	154.01M	51.76M	63.26M
Investing Cash Flow	-206.10M	-184.98M	-128.63M	-9.12M	-4.52M	-193.91M
Financing Cash Flow	-33.88M	-63.78M	-56.13M	-48.09M	-64.47M	-39.44M

Crystalvue Medical Co Ltd Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:6527 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TW:6527	71Outperform	TWD 1.86B	12.15	―	3.98%	-1.23%	10.20%
TW:4153	69Neutral	TWD 1.74B	15.93	―	6.48%	9.73%	36.89%
TW:4116	62Neutral	TWD 1.82B	2.38	―	4.91%	3.85%	786.65%
TW:6517	59Neutral	TWD 1.71B	22.31	―	2.72%	-16.82%	31.08%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:6796	40Underperform	TWD 2.04B	123.00	―	0.51%	12.26%	―

* General Sector Average

Performance Comparison

TW:6527 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:6527	Crystalvue Medical Co Ltd	72.90	-5.53	-7.05%
TW:4116	BenQ Medical Technology Corp.	40.70	-2.63	-6.06%
TW:4153	Diva Laboratories, Ltd.	30.85	-1.80	-5.51%
TW:6517	Baso Precision Optics Ltd.	55.20	-3.17	-5.43%
TW:6796	Medimaging Integrated Solution Inc.	49.20	-39.14	-44.31%
TW:7881	Eyecare Tech, Inc.	73.20	-35.89	-32.90%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026

Crystalvue Medical Co Ltd AI Stock Analysis